Equities Analysts Issue Forecasts for X4 Pharmaceuticals, Inc.’s Q1 2024 Earnings (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc. (NASDAQ:XFORFree Report) – Analysts at B. Riley issued their Q1 2024 earnings per share estimates for shares of X4 Pharmaceuticals in a research note issued on Friday, March 22nd. B. Riley analyst K. Patel anticipates that the company will post earnings of ($0.14) per share for the quarter. B. Riley currently has a “Neutral” rating and a $1.00 target price on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.50) per share. B. Riley also issued estimates for X4 Pharmaceuticals’ Q2 2024 earnings at ($0.16) EPS, Q3 2024 earnings at ($0.17) EPS and Q4 2024 earnings at ($0.18) EPS.

Separately, HC Wainwright reiterated a “buy” rating and issued a $3.00 price objective on shares of X4 Pharmaceuticals in a report on Friday.

Read Our Latest Stock Report on XFOR

X4 Pharmaceuticals Price Performance

X4 Pharmaceuticals stock opened at $1.46 on Monday. The stock has a 50-day moving average price of $0.91 and a two-hundred day moving average price of $0.88. X4 Pharmaceuticals has a 12 month low of $0.57 and a 12 month high of $2.58. The company has a market capitalization of $245.19 million, a PE ratio of -2.43 and a beta of 0.44. The company has a current ratio of 5.34, a quick ratio of 5.34 and a debt-to-equity ratio of 1.07.

Insider Activity at X4 Pharmaceuticals

In other news, CFO Adam S. Mostafa sold 52,500 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $0.88, for a total value of $46,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CFO Adam S. Mostafa sold 52,500 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $0.88, for a total value of $46,200.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Adam S. Mostafa sold 27,721 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $1.01, for a total transaction of $27,998.21. Following the sale, the chief financial officer now directly owns 52,500 shares of the company’s stock, valued at approximately $53,025. The disclosure for this sale can be found here. Insiders sold 185,708 shares of company stock worth $170,428 over the last three months. Company insiders own 1.08% of the company’s stock.

Hedge Funds Weigh In On X4 Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of XFOR. Principal Financial Group Inc. bought a new position in shares of X4 Pharmaceuticals in the 2nd quarter worth about $27,000. ProShare Advisors LLC acquired a new stake in X4 Pharmaceuticals during the second quarter worth approximately $31,000. Bayesian Capital Management LP bought a new stake in X4 Pharmaceuticals in the fourth quarter worth approximately $33,000. SG Americas Securities LLC acquired a new position in X4 Pharmaceuticals in the third quarter valued at approximately $37,000. Finally, Private Advisor Group LLC bought a new position in shares of X4 Pharmaceuticals during the 2nd quarter worth approximately $38,000. Institutional investors and hedge funds own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

(Get Free Report)

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia.

Featured Stories

Earnings History and Estimates for X4 Pharmaceuticals (NASDAQ:XFOR)

Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.